Vaccines against Strep A are accelerating towards clinical trials and glycoconjugate vaccines are likely to be an important component of formulations moving forward. Glycoconjugate vaccines are of interest to promote a long-lived anti-polysaccharide response against the conserved Group A Carbohydrate (GAC). The carrier protein in glycoconjugates is typically a toxoid protein to promote a strong immune response, such as tetanus toxoid or CRM, but increasingly species-specific protein carriers have been employed to provide a double-hit approach to glycoconjugate vaccines. Further, there are several methods to produce glycoconjugates including classic chemical conjugation, bioconjugation and multiple antigen presenting systems (MAPS). These methods all have advantages and disadvantages to their production and use in vaccines including cost, ease/control of production and immune response. Our aim is to compare these methods of glycoconjugate production to assess their production, physicochemical properties and immunogenicity. We are using SpyAD as a representative protein vaccine antigen and both wild type GAC and polyrhamnose (RhaPS). SpyAD-GAC is produced with chemical methods using EDC, a bioconjugate with PglB in E. coli cells, and MAPS by fusion of a biotin binding domain to SpyAD and biotinylating GAC. This study will help to inform thinking towards a cost effective, stable and strongly immunogenic glycoconjugate vaccine against Strep A infections.